Imatinib Resistance Mutation Analysis IRMA Test
Introduction to the Imatinib Resistance Mutation Analysis IRMA Test
The Imatinib Resistance Mutation Analysis IRMA Test is a specialized diagnostic tool used to identify mutations in the BCR-ABL gene that confer resistance to Imatinib, a critical medication used in the treatment of chronic myeloid leukemia (CML). Understanding these mutations is essential for oncologists as it enables them to make informed decisions about treatment strategies, ensuring that patients receive the most effective therapies available.
What the Test Measures
This test measures specific mutations in the BCR-ABL gene that can lead to resistance against Imatinib. By identifying these mutations, healthcare providers can assess the likelihood of treatment failure and adapt the therapeutic approach accordingly.
Who Should Consider This Test
Patients who are currently undergoing treatment for chronic myeloid leukemia (CML) or those who have experienced a relapse may benefit from this test. Key indicators for considering the Imatinib Resistance Mutation Analysis IRMA Test include:
- Persistent symptoms despite treatment
- Rising BCR-ABL levels in quantitative tests
- History of treatment failure with Imatinib
Benefits of Taking the Test
Taking the Imatinib Resistance Mutation Analysis IRMA Test offers several benefits, including:
- Personalized treatment plans based on specific mutations
- Improved chances of treatment success
- Early detection of resistance, allowing timely adjustments to therapy
Understanding Your Results
Results from the Imatinib Resistance Mutation Analysis IRMA Test will indicate the presence or absence of mutations associated with resistance to Imatinib. Your healthcare provider will discuss the implications of these results, helping you understand the next steps in your treatment plan.
Test Information and Pricing
| Test Name | Discount Price | Regular Price |
|---|---|---|
| Imatinib Resistance Mutation Analysis IRMA Test | 210000 NGN | 202800 NGN |
How to Book the Test
To book the Imatinib Resistance Mutation Analysis IRMA Test, please contact us at +2348077798758 or visit our website. Ensure to submit the latest BCR-ABL Quantitative report along with your sample. The turnaround time for results is typically one week, with samples needing to be submitted by Monday at 11 AM for a Saturday report.
Sample Requirements
The sample required for this test is 4 mL (2 mL min.) of whole blood collected in a Lavender Top (EDTA) tube. It is crucial to ship the sample refrigerated and avoid freezing it.
For optimal patient care and management of chronic myeloid leukemia, the Imatinib Resistance Mutation Analysis IRMA Test is an invaluable resource. Book your test today to ensure the best possible outcomes for your treatment journey.
